For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Tirzepatide - Diabetes Mellitus
PAD Profile : Tirzepatide - Diabetes Mellitus
Traffic Light Status
Status 1 of 1.
- Subcutaneous injection (sc)
Guidelines
The following guidelines are available for this indication.
Other Drugs
- Dapagliflozin
- Exenatide
- Insulin detemir
- Liraglutide
- Pioglitazone hydrochloride
- Sitagliptin
- Vildagliptin
- Saxagliptin
- Linagliptin
- Alogliptin
- Empagliflozin
- Xultophy
- Metformin hydrochloride
- Insulin Glargine - Toujeo
- Dulaglutide
- Insulin glargine - Abasaglar
- Insulin degludec
- Insulin aspart - NovoRapid
- Insulin glulisine - Apidra
- Insulin Lispro - Admelog
- Gliclazide
- Acarbose
- Insulin Aspart - Trurapi
- Repaglinide
- Glimepiride
- Glipizide
- Glibenclamide
- Tolbutamide
- Albiglutide
- Insulin pump - Type 1 diabetes
- Semaglutide
- Ertugliflozin
- Suliqua (Insulin glargine/lixisenatide)
- Glyxambi (Linagliptin/empagliflozin)
- Sotagliflozin
- Semaglutide (oral)
- Metformin hydrochloride/sitagliptin
- Metformin hydrochloride/vildagliptin
- Alogliptin/metformin
- Linagliptin/metformin
- Empagliflozin/metformin
- Canagliflozin/metformin
- Dapagliflozin/metformin
- Saxagliptin/dapagliflozin
- Metformin hydrochloride/pioglitazone
- Diazoxide
- Glucose
- Soluble insulin - Hypurin porcine neutral
- Insulin Lispro - Lyumjev
- Insulin Lispro - Humalog
- Insulin Aspart - Fiasp
- Soluble insulin - Humulin R
- Soluble insulin - Humulin S
- Soluble insulin - Actrapid
- Insulin glargine - Lantus
- Insulin glargine - Semglee
- Isophane (neutral insulin) - hypurin porcine 30/70
- Biphasic Isophane Insulin - Humulin M3
- Biphasic Insulin Aspart - Novmix 30
- Biphasic Lispro Insulin - Humalog Mix 25
- Biphasic Lispro Insulin - Humalog Mix 50
- Isophane Insulin - Hypurin Porcine Isophane
- Isophane Insulin - Insulatard
- Isophane Insulin - Humulin I
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
The Surrey Heartlands Integrated Care System Area Prescribing Committee (APC) approves tirzepatide, a long-acting dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist for treating type 2 diabetes in line with the recommendations made in NICE TA924.
Tirzepatide will be given a GREEN traffic light status for this indication.
Dulaglutide remains the preferred choice among GLP-1 options for weekly injections and semaglutide stands as an alternative to dulaglutide for weekly injections.
Please consider tirzepatide as a third line option to dulaglutide and semaglutide weekly injection, only if:
· dulaglutide and semaglutide are unsuitable.
or
the supply of dulaglutide and semaglutide weekly injections is unavailable.